Status:
COMPLETED
Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Neuromuscular Blockade
ECT
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to the brain to produce generalized seizures for the treatment of selected psychiatric disorders such as s...
Detailed Description
Patients, who consent to participate in the study, will randomly receive either succinylcholine or rocuronium by utilizing the Dixon's up and down technique. For patient safety, the first dose of eith...
Eligibility Criteria
Inclusion
- Adult patients (age 18-80) scheduled for ECT treatment at the MGH
Exclusion
- Contraindication to the use of neuromuscular blocking drugs (e.g. allergy, preexisting muscular disease, and history of malignant hyperthermia)
- Malnutrition, general weakness
- Neurological or neuromuscular disease, including paralysis
- Liver disease with liver function test 2x greater than upper normal limit
- Kidney disease with eGFR\<60
- Electrolyte abnormalities with values outside of the normal range
- Pregnancy
- Cardiac disease or abnormal EKG
- Medications that affect seizure threshold or blood pressure response
- Unwilling to participate in the study
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01441960
Start Date
May 1 2011
End Date
February 1 2015
Last Update
June 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114